Literature DB >> 28068153

Prediction of Fibrosis Progression Rate in Patients with Chronic Hepatitis C Genotype 4: Role of Cirrhosis Risk Score and Host Factors.

Tarek Besheer1, Mahmoud El-Bendary1, Hatem Elalfy1, Mohamed Abd El-Maksoud1, Mohamed Salah1, Khaled Zalata2, Wagdi Elkashef2, Heba Elshahawy3, Doaa Raafat3, Wafaa Elemshaty3, Noha Almashad3, Hosam Zaghloul3, Abdel-Hady El-Gilany4, Ahmed Abdel Khalek Abdel Razek5, Mohamed Abd Elwahab6.   

Abstract

The rate of liver fibrosis progression in chronic hepatitis C (CHC) patients is highly variable and affected by different factors. This study aimed to assess the role of cirrhosis risk score (CRS) based on 7 genetic variants (7 single-nucleotide polymorphisms [SNPs]) and host factors (age and sex) in the prediction of the rate of fibrosis progression in CHC. Duration of infection was determined in 115 patients. The fibrosis progression rate (FPR) per year was calculated as the ratio between fibrosis stage and the duration of infection. SNP genotyping were performed and CRS was determined based on it. FPR was significantly elevated in patients who acquired infection at age >40 years versus those who acquired infection at 30-40 years and those who acquired infection at <30 years. Median FPR was significantly higher in males than females (0.17 vs. 0.15) with P = 0.001. CRS value ≥0.8 is predictive of patients with high risk for cirrhosis, and CRS value <0.5 is predictive of patients with low risk for cirrhosis. There was significant positive correlation between CRS and FPR (P ≤ 0.001). CRS based on 7 SNPs at cutoff value ≥0.8, age at infection >40 years, and male sex are predictors of higher FPR.

Entities:  

Keywords:  CHC; cirrhosis risk score; fibrosis progression; host factors

Mesh:

Substances:

Year:  2017        PMID: 28068153     DOI: 10.1089/jir.2016.0111

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  7 in total

1.  Association of Vitamin D Gene Polymorphisms With HCV Infection Outcome.

Authors:  M Neamatallah; M S Serria; M El-Bendary; A-H El-Gilany; A Alhawarey; S Abed; Y A Setate; O A Ammar
Journal:  Br J Biomed Sci       Date:  2022-03-23       Impact factor: 2.432

2.  Cardiac health in patients with hepatitis B virus-related cirrhosis.

Authors:  Wei Yuan; Hong-Zhou Lu; Xue Mei; Yu-Yi Zhang; Zheng-Guo Zhang; Ying Zou; Jie-Fei Wang; Zhi-Ping Qian; Hong-Ying Guo
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

3.  Diagnosing the Stage of Hepatitis C Using Machine Learning.

Authors:  Muhammad Bilal Butt; Majed Alfayad; Shazia Saqib; M A Khan; Munir Ahmad; Muhammad Adnan Khan; Nouh Sabri Elmitwally
Journal:  J Healthc Eng       Date:  2021-12-10       Impact factor: 2.682

4.  Seven gene signature explores the impact of DAAs on the appearance of hepatocellular carcinoma in HCV infected patients.

Authors:  Reham M Dawood; Mai Abd El-Meguid; Hend Ibrahim Shousha; Ahmed Elsayed; Mohamed Mahmoud Nabeel; Ayman Yosry; Ashraf Abdelaziz; Ghada M Salum
Journal:  Heliyon       Date:  2022-08-08

Review 5.  Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.

Authors:  Naoto Fujiwara; Scott L Friedman; Nicolas Goossens; Yujin Hoshida
Journal:  J Hepatol       Date:  2017-10-06       Impact factor: 30.083

6.  Hepatic microenvironment underlies fibrosis in chronic hepatitis B patients.

Authors:  Qun-Yan Yao; Ya-Dong Feng; Pei Han; Feng Yang; Guang-Qi Song
Journal:  World J Gastroenterol       Date:  2020-07-21       Impact factor: 5.742

7.  Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study.

Authors:  Yuko Nagaoki; Hideyuki Hyogo; Yuwa Ando; Yumi Kosaka; Shinsuke Uchikawa; Yuno Nishida; Yuji Teraoka; Kei Morio; Hatsue Fujino; Atsushi Ono; Takashi Nakahara; Eisuke Murakami; Masami Yamauchi; Wataru Okamoto; Tomokazu Kawaoka; Masataka Tsuge; Akira Hiramatsu; Daiki Miki; Michio Imamura; Shoichi Takahashi; Kazuaki Chayama; Hiroshi Aikata
Journal:  BMC Gastroenterol       Date:  2021-07-31       Impact factor: 3.067

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.